EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	mobocertinib Sensitive: A1 - Approval mobocertinib Sensitive : A1	mobocertinib Sensitive: A1 - Approval mobocertinib Sensitive : A1
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	sunvozertinib Sensitive: A1 - Approval sunvozertinib Sensitive : A1	sunvozertinib Sensitive: A1 - Approval sunvozertinib Sensitive : A1
EGFR exon 20 insertion	Lung Non-Squamous Non-Small Cell Cancer	EGFR exon 20 insertion	Lung Non-Squamous Non-Small Cell Cancer	amivantamab-vmjw Sensitive: A2 - Guideline amivantamab-vmjw Sensitive : A2	amivantamab-vmjw Sensitive: A2 - Guideline amivantamab-vmjw Sensitive : A2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	CLN-081 Sensitive: B - Late Trials CLN-081 Sensitive : B	CLN-081 Sensitive: B - Late Trials CLN-081 Sensitive : B
EGFR exon 20 insertion	Lung Non-Small Cell Squamous Cancer	EGFR exon 20 insertion	Lung Non-Small Cell Squamous Cancer	EGFR inhibitor Sensitive: B - Late Trials EGFR inhibitor Sensitive : B	EGFR inhibitor Sensitive: B - Late Trials EGFR inhibitor Sensitive : B
EGFR exon 20 insertion	Lung Non-Squamous Non-Small Cell Cancer	EGFR exon 20 insertion	Lung Non-Squamous Non-Small Cell Cancer	firmonertinib Sensitive: B - Late Trials firmonertinib Sensitive : B	firmonertinib Sensitive: B - Late Trials firmonertinib Sensitive : B
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	cetuximab + afatinib Sensitive: C2 – Inclusion Criteria cetuximab + afatinib Sensitive : C2	cetuximab + afatinib Sensitive: C2 – Inclusion Criteria cetuximab + afatinib Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	osimertinib Sensitive: C2 – Inclusion Criteria osimertinib Sensitive : C2	osimertinib Sensitive: C2 – Inclusion Criteria osimertinib Sensitive : C2
EGFR exon 20 insertion	Solid Tumor	EGFR exon 20 insertion	Solid Tumor	BDTX-189 Sensitive: C2 – Inclusion Criteria BDTX-189 Sensitive : C2	BDTX-189 Sensitive: C2 – Inclusion Criteria BDTX-189 Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2

EGFR exon 20 insertion

Associations